Jefferies Financial Group’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-25,100
Closed -$254K 1710
2023
Q4
$254K Sell
25,100
-770
-3% -$6.76K ﹤0.01% 1422
2023
Q3
$202K Buy
25,870
+770
+3% +$6.6K ﹤0.01% 1342
2023
Q2
$207K Buy
+25,100
New +$219K ﹤0.01% 1427
2023
Q1
Sell
-104,223
Closed -$924K 1719
2022
Q4
$924K Buy
+104,223
New +$1.14M 0.01% 896

Other funds holding EDIT

Jefferies Financial Group's EDIT Position: Q1 2024 in Review

Jefferies Financial Group sold out of Editas Medicine (EDIT) in Q1 2024, closing a stake of 25,100 shares — an estimated $254K sold.

Jefferies Financial Group first reported a position in EDIT in Q4 2022 and held it in 4 quarters. The position peaked at $924K in Q4 2022. 225 funds tracked by Wall St. Rank hold EDIT as of Q1 2024.

  • Jefferies Financial Group reported no remaining Editas Medicine position as of Q1 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 25,100 Editas Medicine shares in Q1 2024, an estimated $254K.
  • Jefferies Financial Group first reported a position in Editas Medicine in Q4 2022 and held it in 4 quarters.
  • Jefferies Financial Group's Editas Medicine position peaked at $924K in Q4 2022.
  • 225 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2024.

Based on Jefferies Financial Group's 13F filing for Q1 2024, filed 13 May 2024.